ANGLE PLC (AIM: AGL, OTCQX: ANPCY), a leader in liquid biopsy technology, has revealed a major contract acquisition with Artios Pharma.
ANGLE PLC (AIM: AGL, OTCQX: ANPCY), a leader in liquid biopsy technology, has revealed a major contract acquisition with Artios Pharma.
ANGLE PLC (AIM: AGL, OTCQX: ANPCY), a liquid biopsy company, announced that it achieved a significant milestone in 2022, with clearance from the US Food & Drug Administration (FDA) and
ANGLE PLC (AIM: AGL, OTCQX: ANPCY) has signed an agreement with Crescendo Biologics, a clinical-stage immuno-oncology company, to offer its advanced Portrait Flex Assay, a liquid biopsy tool, for a
CTCs, CTC clusters and CTC-WBC clusters harvested using Parsortix were more numerous and more aggressive in initiating metastasis during sleep
PARSORTIX ENABLES MOLECULAR CHARACTERISATION OF CTCS ISOLATED FROM FROZEN SAMPLES IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND SARCOMA
14 October 2021 – Poolbeg Pharma (AIM: POLB), ‘Poolbeg’ or the ‘Company’, a clinical stage infectious disease pharmaceutical company with a capital light clinical model, provides an update on new
7 October 2021 – Poolbeg Pharma (AIM: POLB), Poolbeg’ or the ‘Company’, a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has partnered with leading global
Investors snapped up shares in biotech company Oxford Nanopore after its IPO this morning, with the shares soaring 45 per cent.